Adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP

{
  "id": "MLC-T-ONC-009677",
  "term": "Adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP",
  "field": "Oncology and biomedicine",
  "definition": "An off-the-shelf neoantigen priming vaccine comprised of a great ape adenovirus (GAd) encoding tumor-specific neoantigens (TSNAs) derived from as of yet undisclosed frameshift peptides (FSPs) with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of the adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP, the adenovirus infects cells and expresses the TSNAs. This stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TSNAs, leading to tumor cell lysis. Adenoviral-TSNA priming vaccine GAd-209-FSP is followed by boosting with a vaccine that encodes the same target TSNAs.",
  "synonyms": [
    "GAd-209-FSP",
    "great ape adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/adenoviral-tumor-specific-neoantigen-priming-vaccine-gad-209-fsp/"
}